ClinicalTrials.gov
ClinicalTrials.gov Menu

To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study (EREMUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00870038
Recruitment Status : Unknown
Verified March 2009 by Ospedale della Misericordia.
Recruitment status was:  Not yet recruiting
First Posted : March 26, 2009
Last Update Posted : July 22, 2010
Sponsor:
Information provided by:
Ospedale della Misericordia

Brief Summary:
The investigators sought to discover which one of the following strategies is the safest for patients undergoing percutaneous coronary intervention: paclitaxel-coated balloon+Genous stent; Genous stent; drug eluting stent (paclitaxel).

Condition or disease Intervention/treatment Phase
Angioplasty, Transluminal, Percutaneous Coronary Percutaneous Coronary Intervention Device: Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent Device: Percutaneous coronary intervention: Uncoated balloon + Genous stent Device: Percutaneous coronary intervention: Drug eluting stent (Taxus stent) Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Early Re-Endothelialization Might Not be the Unique Solution to Prevent Restenosis. The EREMUS Study
Study Start Date : December 2010
Estimated Primary Completion Date : August 2011
Estimated Study Completion Date : January 2012

Arm Intervention/treatment
Experimental: 1
Paclitaxel eluting balloon (Elutax) + Genous stent
Device: Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent
Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
Other Names:
  • Elutax balloon, Aachen Resonance GmbH, Bavaria, Germany;
  • Genous stent, Orbus Neich, Fort Lauderdale, FL.
Experimental: 2
Uncoated balloon + Genous stent
Device: Percutaneous coronary intervention: Uncoated balloon + Genous stent
Predilatation with uncoated balloon, the stenting with Genous stent.
Other Name: Genous stent, Orbus Neich, Fort Lauderdale, FL.
Active Comparator: 3
Drug eluting stent (Taxus stent)
Device: Percutaneous coronary intervention: Drug eluting stent (Taxus stent)
Predilatation with uncoated balloon, the placement of a Taxus stent.
Other Name: Taxus stent, Boston Scientific, Natick, MA.



Primary Outcome Measures :
  1. Late luminal loss between the three groups at 6 months angiographic follow up. [ Time Frame: 6 months ]
  2. Percent of stent struts covered by endothelium at optical coherence tomography, during 6 months angiographic follow up. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Angiographic restenosis (6 months angiographic follow up). [ Time Frame: 6 months ]
  2. Net adverse clinical events at 6 months (death, myocardial infarction, target lesion revascularization, bleedings as from Acuity scale). [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stable or unstable angina pectoris suitable to PCI of at least one coronary vessel
  • Age >18 years

Exclusion Criteria:

  • Recent (<72 hours) acute myocardial infarction
  • Creatinine clearance <40 ml/min
  • Allergy or hypersensitivity to at least two between: aspirin, clopidogrel, heparin, bivalirudin, paclitaxel, contrast media
  • Life expectancy <1 year

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00870038


Contacts
Contact: Bernardo Cortese, MD +39 02 55033507 bcortese@gmail.com
Contact: Ugo Limbruno, MD, PhD bcortese@gmail.com

Locations
Italy
U.O. Emodinamica, Ospedale della Misericordia Not yet recruiting
Grosseto, Italy, 58100
Principal Investigator: Bernardo Cortese, MD         
Sponsors and Collaborators
Ospedale della Misericordia
Investigators
Principal Investigator: Bernardo Cortese, MD, FESC Ospedale Maggiore Policlinico, Milano, Italy

Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bernardo Cortese, Ospedale della Misericordia
ClinicalTrials.gov Identifier: NCT00870038     History of Changes
Other Study ID Numbers: Bernard1
First Posted: March 26, 2009    Key Record Dates
Last Update Posted: July 22, 2010
Last Verified: March 2009

Keywords provided by Ospedale della Misericordia:
PCI
stent
drug eluting stent
reendothelialization
restenosis
Percutaneous Coronary Angioplasty

Additional relevant MeSH terms:
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action